23 - References

References

894 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 11 References

1. Kroon LA. Drug interactions with smoking. Am J Health Syst Pharm 2007; 64:1917–1921.
2. Scherf-­Clavel M, et al. Analysis of smoking behavior on the pharmacokinetics of antidepressants and antipsychotics: evidence for the role of alternative pathways apart from CYP1A2. Int Clin Psychopharmacol 2019; 34:93–100.
3. Desai HD, et al. Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective. CNS Drugs 2001; 15:469–494.
4. Faber MS, et al. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin Pharmacol Ther 2004; 76:178–184.
5. Servier Laboratories Limited. Summary of product characteristics. Valdoxan (agomelatine). 2021; https://www.medicines.org.uk/emc/ medicine/21830.
6. Miller LG. Recent developments in the study of the effects of cigarette smoking on clinical pharmacokinetics and clinical pharmacodynamics. Clin Pharmacokinet 1989; 17:90–108.
7. Goff DC, et al. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am J Psychiatry 1992; 149:1189–1194.
8. Haring C, et al. Influence of patient-­related variables on clozapine plasma levels. Am J Psychiatry 1990; 147:1471–1475.
9. Diaz FJ, et al. Estimating the size of the effects of co-­medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. Pharmacopsychiatry 2008; 41:81–91.
10. Tsuda Y, et al. Meta-­analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine. BMJ Open 2014; 4:e004216.
11. Flanagan RJ, et al. Effect of cigarette smoking on clozapine dose and on plasma clozapine and N-­desmethylclozapine (norclozapine) concentrations in clinical practice. J Clin Psychopharmacol 2023; 43:514–519.
12. Tsukahara M, et al. Effect of smoking habits and concomitant valproic acid use on relapse in patients with treatment-­resistant schizophrenia receiving clozapine: a 1-­year retrospective cohort study. Acta Psychiatr Scand 2023; 148:437–446.
13. Augustin M, et  al. Effect of fluvoxamine augmentation and smoking on clozapine serum concentrations. Schizophr Res 2019; 210:143–148.
14. Qurashi I, et al. Changes in smoking status, mental state and plasma clozapine concentration: retrospective cohort evaluation. BJPsych Bull 2019; 43:271–274.
15. Fric M, et al. The influence of smoking on the serum level of duloxetine. Pharmacopsychiatry 2008; 41:151–155.
16. Augustin M, et al. Differences in duloxetine dosing strategies in smoking and nonsmoking patients: therapeutic drug monitoring uncovers the impact on drug metabolism. J Clin Psychiatry 2018; 79:17m12086.
17. Scherf-­Clavel M, et al. Smoking is associated with lower dose-­corrected serum concentrations of escitalopram. J Clin Psychopharmacol 2019; 39:485–488.
18. Ereshefsky L, et al. Effects of smoking on fluphenazine clearance in psychiatric inpatients. Biol Psychiatry 1985; 20:329–332.
19. Spigset O, et al. Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. Clin Pharmacol Ther 1995; 58:399–403.
20. Jann MW, et  al. Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance. Psychopharmacology (Berl) 1986; 90:468–470.
21. Shimoda K, et al. Lower plasma levels of haloperidol in smoking than in nonsmoking schizophrenic patients. Ther Drug Monit 1999; 21:293–296.
22. Takahashi LH, et al. Effect of smoking on the pharmacokinetics of inhaled loxapine. Ther Drug Monit 2014; 36:618–623.
23. Grasmader K, et al. Population pharmacokinetic analysis of mirtazapine. Eur J Clin Pharmacol 2004; 60:473–480.
24. Carrillo JA, et al. Role of the smoking-­induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-­state concentration of olanzapine. J Clin Psychopharmacol 2003; 23:119–127.
25. Lowe EJ, et  al. Impact of tobacco smoking cessation on stable clozapine or olanzapine treatment. Ann Pharmacother 2010; 44:727–732.
26. Horvat M, et al. Association of smoking cigarettes, age, and sex with serum concentrations of olanzapine in patients with schizophrenia. Biochem Med (Zagreb) 2023; 33:030702.
27. Schoretsanitis G, et al. Effect of smoking on risperidone pharmacokinetics – a multifactorial approach to better predict the influence on drug metabolism. Schizophr Res 2017; 185:51–57.
28. Schoretsanitis G, et al. Lack of smoking effects on pharmacokinetics of oral paliperidone—­analysis of a naturalistic therapeutic drug monitoring sample. Pharmacopsychiatry 2021; 54:31–35.
29. Ishida M, et al. Effects of various factors on steady state plasma concentrations of trazodone and its active metabolite m-­chlorophenylpiperazine. Int Clin Psychopharmacol 1995; 10:143–146.
30. Ereshefsky L, et al. Pharmacokinetic factors affecting antidepressant drug clearance and clinical effect: evaluation of doxepin and imipramine – new data and review. Clin Chem 1988; 34:863–880.
31. Lundstrøm NH, et al. The effect of smoking on the plasma concentration of tricyclic antidepressants: a systematic review. Acta Neuropsychiatr 2022; 34:1–9.
32. Jann MW, et al. Clinical pharmacokinetics of the depot antipsychotics. Clin Pharmacokinet 1985; 10:315–333.
33. Jorgensen A, et  al. Zuclopenthixol decanoate in schizophrenia: serum levels and clinical state. Psychopharmacology (Berl) 1985; 87:364–367.
34. Blacker CJ. Clinical issues to consider for clozapine patients who vape: a case illustration. Focus (Am Psychiatr Publ) 2020; 18:55–57.
35. Montville DJ, et al. Fluctuation between cigarette smoking and use of electronic nicotine delivery systems: impact on clozapine concentrations and clinical effect. Ment Health Clin 2021; 11:365–368.